Medications Underutilized for Treating Youth Opioid Abuse
Few young people aged 13 to 25 receiving buprenorphine or naltrexone
MONDAY, June 19, 2017 (HealthDay News) -- The rate of opioid addiction among Americans age 25 and under rose nearly six-fold from 2001 to 2014, but few are receiving medical treatment that might prevent overdose or relapse, according to a report published online June 19 in JAMA Pediatrics.
Scott Hadland, M.D., M.P.H., an assistant professor of pediatrics at the Boston University School of Medicine, and colleagues reviewed private insurance claims data to identify teens and young adults, ages 13 to 25, diagnosed with an opioid addiction from 2001 through June 2014. Out of almost 10 million patients overall, they found that 20,822 got an addiction diagnosis, at an average age of 21. That rate increased nearly six times from 2001 to 2014.
Although the number of patients treated with either buprenorphine or naltrexone increased significantly from 2002 to 2009, it decreased in 2014, the researchers found. Over the study period, only 26.8 percent of young people treated for addiction to prescription opioids or heroin received either buprenorphine or naltrexone. The youngest patients, females, blacks, and Hispanics were less likely to be given either drug than other addicts. Of the 5,580 individuals who received either buprenorphine or naltrexone within six months of diagnosis, nine out of 10 got buprenorphine (89.2 percent). Of 16- and 17-year-olds, only one in 10 received one of the medications (9.5 percent). For those 15 and younger, only 1.4 percent did.
"Adolescents might especially be underserved in the current treatment environment," the authors write. "In the face of a worsening opioid crisis in the United States, strategies to expand the use of pharmacotherapy for adolescents and young adults are greatly needed, and special care is warranted to ensure equitable access for all affected youth to avoid exacerbating health disparities"